Reviewing Vericel (NASDAQ:VCEL) & Atara Biotherapeutics (NASDAQ:ATRA)

Vericel (NASDAQ:VCEL) and Atara Biotherapeutics (NASDAQ:ATRA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.

Valuation & Earnings

This table compares Vericel and Atara Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$197.52 million	14.43	-$3.18 million	$0.06	962.83
Atara Biotherapeutics	$8.57 million	8.19	-$276.13 million	($25.78)	-0.47

Vericel has higher revenue and earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vericel has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Insider & Institutional Ownership

70.9% of Atara Biotherapeutics shares are owned by institutional investors. 7.2% of Vericel shares are owned by company insiders. Comparatively, 3.7% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vericel and Atara Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vericel	1.56%	1.48%	0.96%
Atara Biotherapeutics	-132.58%	N/A	-90.16%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Vericel and Atara Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0	0	7	0	3.00
Atara Biotherapeutics	1	1	2	0	2.25

Vericel currently has a consensus target price of $59.71, suggesting a potential upside of 3.38%. Atara Biotherapeutics has a consensus target price of $16.67, suggesting a potential upside of 36.84%. Given Atara Biotherapeutics’ higher possible upside, analysts clearly believe Atara Biotherapeutics is more favorable than Vericel.

Summary

Vericel beats Atara Biotherapeutics on 12 of the 14 factors compared between the two stocks.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.